Merus to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced CEO Bill Lundberg's participation in several upcoming investor conferences. Key events include a panel discussion at Citi’s 16th Annual BioPharma Virtual Conference on September 9, 2021, a pre-recorded presentation at H.C. Wainwright 23rd Annual Global Investment Conference available on September 13, and a presentation at the 2021 Cantor Virtual Global Healthcare on September 27, 2021. The webcasts will be accessible on the company's investor page, with archived presentations available for a limited time.
Details
News Market Reaction – MRUS
The recorded move for MRUS in the trading session of this news was -2.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in the following investor conferences:
- Citi’s 16th Annual BioPharma Virtual Conference (Panel discussion): Thursday, Sept. 9, 2021 at 1:25-2:25 p.m. ET
- H.C. Wainwright 23rd Annual Global Investment Conference (Presentation): Pre-recorded and available starting September 13 at 7:00 a.m. ET
- 2021 Cantor Virtual Global Healthcare (Presentation): Monday, September 27, 2021 at 2:40-3:10 p.m. ET
The webcast of the presentations will be available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.